Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Semarion logo — Turning adherent cells into barcoded reagents to accelerate...

Semarion

Turning adherent cells into barcoded reagents to accelerate drug discovery

Founded 2018 United Kingdom Cambridge, United Kingdom 14 employees Total: $3.80M Biotechnology, Health Care +1

General Information

Company Name Semarion
Founded Year 2018
Location United Kingdom Cambridge, United Kingdom
Employees 14
Industries Biotechnology, Health Care, Health and Wellness
Hiring 1 role posted in the month to 25 Sep 2026
Social

BounceWatch is an independent company data service, not affiliated with Semarion. To contact Semarion, visit semarion.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Actively Hiring Sep 24, 2026

Hiring for 1 position in the last 30 days.

Get alerts when Semarion shows new signals

About Semarion

Semarion is transforming adherent cell assays for next-generation drug discovery. Our SemaCyte® platform turns adherent cells into barcoded, assay-ready, automation-friendly reagents, enabling researchers to multiplex cell models in the same well, miniaturise assays, and generate richer biological data from existing microplate workflows. SemaCytes are ultra-miniaturised, optically barcoded microcarriers that function like microscopic Petri dishes. They carry small groups of adherent cells while preserving 2D morphology, can be handled with standard liquid handlers, cryopreserved for on-demand use, pooled for multiplexed assays, and decoded by high-content imaging. By decoupling cell preparation from assaying and multiplexing cell models, SemaCytes help discovery teams reduce variability, remove scheduling bottlenecks, and increase data throughput by 10× without replacing existing automation or imaging infrastructure. Semarion is based in Cambridge, UK and combines microfabrication, materials science and cell biology to make adherent cell assays more scalable, reproducible and automation-ready. We work with pharmaceutical companies and technology partners across phenotypic screening, antibody discovery, compound profiling and advanced in vitro models.

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Round $3.80M 7
The FSE Group Cambridge Capital Group Oxford Innovation Finance
The FSE Group, Cambridge Capital Group +5
31 Mar 2026

Latest News

View All
Semarion raises $3.8M to scale cell assay technology — Tech
Semarion raises $3.8M to scale cell assay technology
Tech Mar 31, 2026

FAQ About Semarion

Turning adherent cells into barcoded reagents to accelerate drug discovery
Semarion was founded in 2018.
Semarion is headquartered in Cambridge, United Kingdom.
Semarion operates in Biotechnology, Health Care and Health and Wellness.
Semarion has approximately 14 employees.
Semarion has completed 1 funding round, raising a total of $3.80M.

Source: BounceWatch company record for Semarion, https://bouncewatch.com/company/semarion, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes